Get access

Memantine and NMDA Antagonism for Chronic Migraine: A Potentially Novel Therapeutic Approach?

Authors

  • Konstantinos Spengos MD,

    1. From the Department of Neurology, University of Athens School of Medicine, Eginition Hospital, Athens, Greece (K. Spengos); Department of Psychiatry, Neuropsychiatry Unit, University of Athens School of Medicine, Eginition Hospital, Athens, Greece (C. Theleritis and T. Paparrigopoulos).
    Search for more papers by this author
  • Christos Theleritis MD,

    1. From the Department of Neurology, University of Athens School of Medicine, Eginition Hospital, Athens, Greece (K. Spengos); Department of Psychiatry, Neuropsychiatry Unit, University of Athens School of Medicine, Eginition Hospital, Athens, Greece (C. Theleritis and T. Paparrigopoulos).
    Search for more papers by this author
  • Thomas Paparrigopoulos MD

    1. From the Department of Neurology, University of Athens School of Medicine, Eginition Hospital, Athens, Greece (K. Spengos); Department of Psychiatry, Neuropsychiatry Unit, University of Athens School of Medicine, Eginition Hospital, Athens, Greece (C. Theleritis and T. Paparrigopoulos).
    Search for more papers by this author

  • Conflict of Interest: None

  • Clinical Notes

K. Spengos, Department of Neurology, University of Athens School of Medicine, Vas. Sofias 74, Athens 11528, Greece.

Abstract

We present the case of a woman with chronic migraine who unexpectedly reported full remission of headache after memantine, an NMDA receptor antagonist, was administered for treating concomitant mild cognitive impairment. An underlying dose-dependent effect of memantine on headache symptoms in chronic daily headache and chronic migraine could be assumed.

Get access to the full text of this article

Ancillary